Pelthos Therapeutics posts investor deck outlining dermatology portfolio strategy centered on Zelsuvmi launch, Xepi and Xeglyze additions

Reuters2026/08/13 11:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pelthos highlighted commercial traction for Zelsuvmi, with more than 20,000 units dispensed since the July 2025 launch through April 2026.
Portfolio expansion centered on two FDA-approved dermatology assets, Xepi for impetigo and Xeglyze for head lice, to leverage existing infrastructure.
Xepi relaunch targeted for Q1 2027; Xeglyze commercial launch planned for Q3 2027.
Key equity metrics as of 08/10/26: stock price $29; about 9,000,000 shares outstanding; market cap about $260 million.
Cash at end of Q2 2026 totaled $24.2 million; 60-day average daily trading volume about 51,000 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pelthos Therapeutics posts investor deck outlining dermatology portfolio strategy centered on Zelsuvmi launch, Xepi and Xeglyze additions

You may also like

Crypto prices